Obesity-related cardiorenal disease: The benefits of bariatric surgery

Nature Reviews Nephrology

Volumn 9, Issue 9, 2013, Pages 539-551

  Fenske, Wiebke ^a   Athanasiou, Thanos ^b   Harling, Leanne ^b   Drechsler, Christiane ^a   Darzi, Ara ^b   Ashrafian, Hutan ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ALGORITHM; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BLOOD BRAIN BARRIER; BLOOD VESSEL REACTIVITY; BODY COMPOSITION; BODY FAT DISTRIBUTION; CARDIORENAL SYNDROME; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHOLECYSTECTOMY; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; FATTY LIVER; FOLLOW UP; GASTRIC BANDING; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HEART PROTECTION; HEART RATE VARIABILITY; HOSPITAL DISCHARGE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIFESTYLE MODIFICATION; LIPID OXIDATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NEPHROSCLEROSIS; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVERALL SURVIVAL; OXIDATIVE STRESS; PRESSORECEPTOR; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDERED BREATHING; SLEEVE GASTRECTOMY; STOMACH BYPASS; SUDDEN CARDIAC DEATH; SURGICAL MORTALITY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

BARIATRIC SURGERY; HEART DISEASES; HUMANS; INCIDENCE; KIDNEY DISEASES; OBESITY; PREVALENCE; WEIGHT LOSS; WORLD HEALTH;

EID: 84883145916     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.145     Document Type: Review

References (224)

1. WHO. World Health Organisation Fact Sheet No. 311: Obesity and Overweight [online], http://www.who.int/mediacentre/factsheets/fs311/en/index.html (2013).
2. Ford, E. S., Giles, W. H. & Dietz, W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359 (2002).
3. House, A. A. et al. Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol. Dial. Transplant. 25, 1416-1420 (2010).
4. Nelson, R., Antonetti, I., Bisognano, J. D. & Sloand, J. Obesity-related cardiorenal syndrome. J. Clin. Hypertens. (Greenwich) 12, 59-63 (2010).
5. McCullough, P. A. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J. Am. Coll. Cardiol. 41, 725-728 (2003).
6. Sarnak, M. J. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108, 2154-2169 (2003).
7. Brinkworth, G. D., Buckley, J. D., Noakes, M. & Clifton, P. M. Renal function following long-term weight loss in individuals with abdominal obesity on a very-low-carbohydrate diet vs high-carbohydrate diet. J. Am. Diet Assoc. 110, 633-638 (2010).
8. Puterbaugh, J. S. The emperor's tailors: the failure of the medical weight loss paradigm and its causal role in the obesity of America. Diabetes Obes. Metab. 11, 557-570 (2009).
9. Sjöström, L. et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357, 741-752 (2007).
10. Eilat-Adar, S., Eldar, M. & Goldbourt, U. Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am. J. Epidemiol. 161, 352-358 (2005).
11. Algahim, M. F. et al. Progressive regression of left ventricular hypertrophy two years after bariatric surgery. Am. J. Med. 123, 549-555 (2010).
12. Hsuan, C. F. et al. The effect of surgical weight reduction on left ventricular structure and function in severe obesity. Obesity (Silver Spring) 18, 1188-1193 (2010).
13. Navaneethan, S. D. & Yehnert, H. Bariatric surgery and progression of chronic kidney disease. Surg. Obes. Relat. Dis. 5, 662-665 (2009).
14. Zalesin, K. C. & McCullough, P. A. Bariatric surgery for morbid obesity: risks and benefits in chronic kidney disease patients. Adv. Chronic Kidney Dis. 13, 403-417 (2006).
15. Colditz, G. A., Willett, W. C., Rotnitzky, A. & Manson, J. E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med. 122, 481-486 (1995).
16. Han, T. S., Richmond, P., Avenell, A. & Lean, M. E. Waist circumference reduction and cardiovascular benefits during weight loss in women. Int. J. Obes. Relat. Metab. Disord. 21, 127-134 (1997).
17. Wildman, R. P. et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch. Intern. Med. 168, 1617-1624 (2008).
18. Thomas, E. L. et al. The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat. Obesity (Silver Spring) 20, 76-87 (2012).
19. Thomas, E. L. et al. Magnetic resonance imaging of total body fat. J. Appl. Physiol. 85, 1778-1785 (1998).
20. Stefan, N. et al. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 168, 1609-1616 (2008).
21. Karelis, A. D. Metabolically healthy but obese individuals. Lancet 372, 1281-1283 (2008).
22. Primeau, V. et al. Characterizing the profile of obese patients who are metabolically healthy. Int. J. Obes. (Lond.) 35, 971-981 (2011).
23. Kloting, N. et al. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299, E506-E515 (2010).
24. Stefan, N. & Haring, H. U. The metabolically benign and malignant fatty liver. Diabetes 60, 2011-2017 (2011).
25. Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: old questions and new insights. Science 332, 1519-1523 (2011).
26. Grujic, D. et al. Beta3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. J. Biol. Chem. 272, 17686-17693 (1997).
27. Abbott, R. D., Donahue, R. P., Kannel, W. B. & Wilson, P. W. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 260, 3456-3460 (1988).
28. Yamagishi, S. & Imaizumi, T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 11, 2279-2299 (2005).
29. Gerstein, H. C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
30. Griffin, K. A., Kramer, H. & Bidani, A. K. Adverse renal consequences of obesity. Am. J. Physiol. Renal Physiol. 294, F685-F696 (2008).
31. Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J. & D'Agati, V. D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59, 1498-1509 (2001).
32. Alexander, M. P. et al. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am. J. Kidney Dis. 53, 751-759 (2009).
33. Tsuboi, N. et al. Low glomerular density with glomerulomegaly in obesity-related glomerulopathy. Clin. J. Am. Soc. Nephrol. 7, 735-741 (2012).
34. Deji, N. et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am. J. Physiol. Renal Physiol. 296, F118-F126 (2009).
35. Nagase, M. et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J. Am. Soc. Nephrol. 17, 3438-3446 (2006).
36. Nagase, M. et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47, 1084-1093 (2006).
37. Rubler, S. et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595-602 (1972).
38. Galderisi, M. et al. Left ventricular hypertrophy, compliance and ventricular filling. J. Int. Med. Res. 19, 103-111 (1991).
39. Shehadeh, A. & Regan, T. J. Cardiac consequences of diabetes mellitus. Clin. Cardiol. 18, 301-305 (1995).
40. Regan, T. J. et al. Evidence for cardiomyopathy in familial diabetes mellitus. J. Clin. Invest. 60, 884-899 (1977).
41. Alpert, M. A. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am. J. Med. Sci. 321, 225-236 (2001).
42. Poirier, P. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113, 898-918 (2006).
43. Pinna, G. A., Curzu, M. M., Sechi, M., Chelucci, G. & Maciocco, E. Synthesis and dopamine D2-like receptor binding affinity of substituted 5-phenyl-pyrrole-3-carboxamides. Farmaco 54, 542-550 (1999).
44. Hu, R. M., Levin, E. R., Pedram, A. & Frank, H. J. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 42, 351-358 (1993).
45. Kim, J. A., Montagnani, M., Koh, K. K. & Quon, M. J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113, 1888-1904 (2006).
46. Vinik, A. I. The metabolic basis of atherogenic dyslipidemia. Clin. Cornerstone 7, 27-35 (2005).
47. James, W. P. Assessing obesity: are ethnic differences in body mass index and waist classification criteria justified? Obes. Rev. 6, 179-181 (2005).
48. McFarlane, S. I., Banerji, M. & Sowers, J. R. Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab. 86, 713-718 (2001).
49. Sowers, J. R. Insulin resistance and hypertension. Am. J. Physiol. Heart Circ. Physiol. 286, H1597-H1602 (2004).
50. Sowers, J. R., Epstein, M. & Frohlich, E. D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37, 1053-1059 (2001).
51. Edwards, M. S., Craven, T. E., Burke, G. L., Dean, R. H. & Hansen, K. J. Renovascular disease and the risk of adverse coronary events in the elderly: a prospective, population-based study. Arch. Intern. Med. 165, 207-213 (2005).
52. U. S. Renal Data System. USRDS 2003 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States [online], http://www.usrds.org/atlas03.aspx (2003).
53. Dulloo, A. G. Biomedicine. A sympathetic defense against obesity. Science 297, 780-781 (2002).
54. Rossi, M. et al. Cardiac autonomic dysfunction in obese subjects. Clin. Sci. (Lond.) 76, 567-572 (1989).
55. Petretta, M. et al. Assessment of cardiac autonomic control by heart period variability in patients with early-onset familial obesity. Eur. J. Clin. Invest. 25, 826-832 (1995).
56. Grassi, G. et al. Sympathetic activation in obese normotensive subjects. Hypertension 25, 560-563 (1995).
57. Esler, M. et al. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48, 787-796 (2006).
58. Kotsis, V. T., Stabouli, S. V., Papamichael, C. M. & Zakopoulos, N. A. Impact of obesity in intima media thickness of carotid arteries. Obesity (Silver Spring) 14, 1708-1715 (2006).
59. Tentolouris, N., Argyrakopoulou, G. & Katsilambros, N. Perturbed autonomic nervous system function in metabolic syndrome. Neuromolecular Med. 10, 169-178 (2008).
60. Trayhurn, P. & Wood, I. S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 92, 347-355 (2004).
61. Trayhurn, P., Wang, B. & Wood, I. S. Hypoxia and the endocrine and signalling role of white adipose tissue. Arch. Physiol. Biochem. 114, 267-276 (2008).
62. Hak, A. E. et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol. 19, 1986-1991 (1999).
63. Ito, H. et al. Association of serum tumour necrosis factor-alpha with serum low-density lipoprotein-cholesterol and blood pressure in apparently healthy Japanese women. Clin. Exp. Pharmacol. Physiol. 28, 188-192 (2001).
64. Bautista, L. E., Vera, L. M., Arenas, I. A. & Gamarra, G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J. Hum. Hypertens. 19, 149-154 (2005).
65. Tilg, H. & Moschen, A. R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772-783 (2006).
66. Ridker, P. M., Rifai, N., Stampfer, M. J. & Hennekens, C. H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767-1772 (2000).
67. Langenberg, C., Bergstrom, J., Scheidt-Nave, C., Pfeilschifter, J. & Barrett-Connor, E. Cardiovascular death and the metabolic syndrome: role of adiposity-signaling hormones and inflammatory markers. Diabetes Care 29, 1363-1369 (2006).
68. Chae, C. U., Lee, R. T., Rifai, N. & Ridker, P. M. Blood pressure and inflammation in apparently healthy men. Hypertension 38, 399-403 (2001).
69. Vila, E. & Salaices, M. Cytokines and vascular reactivity in resistance arteries. Am. J. Physiol. Heart Circ. Physiol. 288, H1016-H1021 (2005).
70. Virdis, A. & Schiffrin, E. L. Vascular inflammation: a role in vascular disease in hypertension? Curr. Opin. Nephrol. Hypertens. 12, 181-187 (2003).
71. Lagrand, W. K. et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100, 96-102 (1999).
72. Munkhaugen, J., Lydersen, S., Widerøe, T. E. & Hallan, S. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am. J. Kidney Dis. 54, 638-646 (2009).
73. Chakrabarti, S. K. et al. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese zucker rats. Am. J. Physiol. Endocrinol. Metab. 300, E175-E187 (2011).
74. Kuller, L. H., Tracy, R. P., Shaten, J. & Meilahn, E. N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 144, 537-547 (1996).
75. Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P. & Hennekens, C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973-979 (1997).
76. Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432 (1994).
77. Schwartz, M. W., Seeley, R. J., Campfield, L. A., Burn, P. & Baskin, D. G. Identification of targets of leptin action in rat hypothalamus. J. Clin. Invest. 98, 1101-1106 (1996).
78. Marsh, A. J. et al. Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and dorsomedial hypothalamus. Hypertension 42, 488-493 (2003).
79. Rahmouni, K., Morgan, D. A., Morgan, G. M., Mark, A. L. & Haynes, W. G. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 54, 2012-2018 (2005).
80. Correia, M. L. et al. Role of corticotrophin-releasing factor in effects of leptin on sympathetic nerve activity and arterial pressure. Hypertension 38, 384-388 (2001).
81. Haynes, W. G., Sivitz, W. I., Morgan, D. A., Walsh, S. A. & Mark, A. L. Sympathetic and cardiorenal actions of leptin. Hypertension 30, 619-623 (1997).
82. Haynes, W. G., Morgan, D. A., Walsh, S. A., Sivitz, W. I. & Mark, A. L. Cardiovascular consequences of obesity: role of leptin. Clin. Exp. Pharmacol. Physiol. 25, 65-69 (1998).
83. de Courten, M. et al. Hyperleptinaemia: the missing link in the, metabolic syndrome? Diabet. Med. 14, 200-208 (1997).
84. Beltowski, J., Borkowska, E., Wojcicka, G. & Marciniak, A. Regulation of renal ouabain-resistant Na+-ATPase by leptin, nitric oxide, reactive oxygen species, and cyclic nucleotides: implications for obesity-associated hypertension. Clin. Exp. Hypertens. 29, 189-207 (2007).
85. Galletti, F. et al. High-circulating leptin levels are associated with greater risk of hypertension in men independently of body mass and insulin resistance: results of an eight-year follow-up study. J. Clin. Endocrinol. Metab. 93, 3922-3926 (2008).
86. Kramer, C. K., von Muhlen, D. & Barrett-Connor, E. Does leptin predict incident hypertension in older adults? Clin. Endocrinol. (Oxf.) 73, 201-205 (2010).
87. Wolf, G. & Ziyadeh, F. N. Leptin and renal fibrosis. Contrib. Nephrol. 151, 175-183 (2006).
88. Karmazyn, M., Purdham, D. M., Rajapurohitam, V. & Zeidan, A. Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc. Med. 17, 206-211 (2007).
89. Rajapurohitam, V., Gan, X. T., Kirshenbaum, L. A. & Karmazyn, M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ. Res. 93, 277-279 (2003).
90. Selthofer-Relatic, K. et al. Hyperleptinemia - non-haemodynamic risk factor for the left ventricular hypertrophy development in hypertensive overweight females. Coll. Antropol. 32, 681-685 (2008).
91. Umemoto, Y. et al. Leptin stimulates the proliferation of murine myelocytic and primitive hematopoietic progenitor cells. Blood 90, 3438-3443 (1997).
92. Paolisso, G. et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 34, 1047-1052 (1999).
93. Leyva, F. et al. Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur. Heart J. 19, 1547-1551 (1998).
94. Purdham, D. M. et al. A neutralizing leptin receptor antibody mitigates hypertrophy and hemodynamic dysfunction in the postinfarcted rat heart. Am. J. Physiol. Heart Circ. Physiol. 295, H441-H446 (2008).
95. Barouch, L. A., Berkowitz, D. E., Harrison, R. W., O'Donnell, C. P. & Hare, J. M. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108, 754-759 (2003).
96. Luo, J. D., Zhang, G. S. & Chen, M. S. Leptin and cardiovascular diseases. Drug News Perspect. 18, 427-431 (2005).
97. Reaux, A. et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J. Neurochem. 77, 1085-1096 (2001).
98. Ishida, J. et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J. Biol. Chem. 279, 26274-26279 (2004).
99. Higuchi, K. et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology 148, 2690-2697 (2007).
100. Bacha, F., Saad, R., Gungor, N. & Arslanian, S. A. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 27, 547-552 (2004).
101. Kadowaki, T. & Yamauchi, T. Adiponectin and adiponectin receptors. Endocr. Rev. 26, 439-451 (2005).
102. Shibata, R. et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 11, 1096-1103 (2005).
103. Hashimoto, N. et al. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism 55, 1653-1657 (2006).
104. Ruano, M. et al. HOMA, QUICKI and MFfm to measure insulin resistance in morbid obesity. Obes. Surg. 16, 549-553 (2006).
105. Kidambi, S. et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 49, 704-711 (2007).
106. Campbell, D. J. Circulating and tissue angiotensin systems. J. Clin. Invest. 79, 1-6 (1987).
107. Briet, M. & Schiffrin, E. L. Aldosterone: effects on the kidney and cardiovascular system. Nat. Rev. Nephrol. 6, 261-273 (2010).
108. Greene, E. L., Kren, S. & Hostetter, T. H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98, 1063-1068 (1996).
109. Ronco, C., Haapio, M., House, A. A., Anavekar, N. & Bellomo, R. Cardiorenal syndrome. J. Am. Coll. Cardiol. 52, 1527-1539 (2008).
110. Kanbay, M. et al. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am. J. Nephrol. 33, 325-331 (2011).
111. Kanbay, M. et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am. J. Nephrol. 33, 298-304 (2011).
112. Anker, S. D. et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107, 1991-1997 (2003).
113. Basar, N. et al. Elevated serum uric acid predicts angiographic impaired reperfusion and 1-year mortality in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention. J. Investig. Med. 59, 931-937 (2011).
114. Masuo, K., Kawaguchi, H., Mikami, H., Ogihara, T. & Tuck, M. L. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42, 474-480 (2003).
115. Johnson, R. J., Herrera-Acosta, J., Schreiner, G. F. & Rodriguez-Iturbe, B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N. Engl. J. Med. 346, 913-923 (2002).
116. Johnson, R. J., Feig, D. I., Herrera-Acosta, J. & Kang, D. H. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 45, 18-20 (2005).
117. Johnson, R. J., Rodriguez-Iturbe, B., Kang, D. H., Feig, D. I. & Herrera-Acosta, J. A unifying pathway for essential hypertension. Am. J. Hypertens. 18, 431-440 (2005).
118. Lv, Q. et al. High serum uric Acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS ONE 8, e56864 (2013).
119. Jin, Y. L. et al. Uric acid levels, even in the normal range, are associated with increased cardiovascular risk: The Guangzhou Biobank Cohort Study. Int. J. Cardiol. http://dx.doi.org/10.1016/j.ijcard.2013.01.214.
120. Lanaspa, M. A. et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J. Biol. Chem. 287, 40732-40744 (2012).
121. Lee, J. E. et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 47, 962-967 (2006).
122. Rosolowsky, E. T. et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin. J. Am. Soc. Nephrol. 3, 706-713 (2008).
123. Iseki, K. et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am. J. Kidney Dis. 44, 642-650 (2004).
124. Ford, E. S., Li, C., Cook, S. & Choi, H. K. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 115, 2526-2532 (2007).
125. Choi, H. K. & Ford, E. S. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am. J. Med. 120, 442-447 (2007).
126. Pacifico, L. et al. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. Eur. J. Endocrinol. 160, 45-52 (2009).
127. Quinones-Galvan, A. & Ferrannini, E. Renal effects of insulin in man. J. Nephrol. 10, 188-191 (1997).
128. Feig, D. I. & Johnson, R. J. Hyperuricemia in childhood primary hypertension. Hypertension 42, 247-252 (2003).
129. Niskanen, L. K. et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch. Intern. Med. 164, 1546-1551 (2004).
130. Hongo, M. et al. Association between serum uric acid levels and cardiometabolic risk factors among Japanese junior high school students. Circ. J. 74, 1570-1577 (2010).
131. Nakagawa, T. et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol. 290, F625-F631 (2006).
132. Khosla, U. M. et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 67, 1739-1742 (2005).
133. Sui, X., Church, T. S., Meriwether, R. A., Lobelo, F. & Blair, S. N. Uric acid and the development of metabolic syndrome in women and men. Metabolism 57, 845-852 (2008).
134. Hallfrisch, J. Metabolic effects of dietary fructose. FASEB J. 4, 2652-2660 (1990).
135. Sanchez-Lozada, L. G. et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol. 294, F710-F718 (2008).
136. Johnson, R. J. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41, 1183-1190 (2003).
137. Mazzali, M. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38, 1101-1106 (2001).
138. Xu, C., Yu, C., Xu, L., Miao, M. & Li, Y. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS ONE 5, e11578 (2010).
139. Lee, J. W. et al. Serum uric acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver 4, 378-383 (2010).
140. Hwang, I. C., Suh, S. Y., Suh, A. R. & Ahn, H. Y. The relationship between normal serum uric acid and nonalcoholic fatty liver disease. J. Korean Med. Sci. 26, 386-391 (2011).
141. Dawson, J. & Walters, M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br. J. Clin. Pharmacol. 62, 633-644 (2006).
142. Ronco, C. et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J. 31, 703-711 (2010).
143. Ashrafian, H., le Roux., C. W., Darzi, A. & Athanasiou, T. Effects of bariatric surgery on cardiovascular function. Circulation 118, 2091-2102 (2008).
144. Lekawanvijit, S., Kompa, A. R., Wang, B. H., Kelly, D. J. & Krum, H. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ. Res. 111, 1470-1483 (2012).
145. Li, J. V. et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 60, 1214-1223 (2011).
146. Fenske, W., Parker, J. & Bloom, S. R. Pharmacotherapy for obesity: a field in crisis? Expert Rev. Endocrinol. Metab. 6, 563-577 (2011).
147. Flum, D. R. et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N. Engl. J. Med. 361, 445-454 (2009).
148. Ashrafian, H., Darzi, A. & Athanasiou, T. Bariatric surgery - can we afford to do it or deny doing it? Frontline Gastroenterol. 2, 82-89 (2011).
149. Buchwald, H. & Oien, D. M. Metabolic/bariatric surgery worldwide 2008. Obes. Surg. 19, 1605-1611 (2009).
150. Carlsson, L. M. et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N. Engl. J. Med. 367, 695-704 (2012).
151. Sjostrom, L. et al. Bariatric surgery and long-term cardiovascular events. JAMA 307, 56-65 (2012).
152. Salem, L., Jensen, C. C. & Flum, D. R. Are bariatric surgical outcomes worth their cost? A systematic review. J. Am. Coll. Surg. 200, 270-278 (2005).
153. Nguyen, N. T. et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann. Surg. 234, 279-289; discussion 289-291 (2001).
154. Buchwald, H. et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am. J. Med. 122, 248-256.e5 (2009).
155. Tice, J. A., Karliner, L., Walsh, J., Petersen, A. J. & Feldman, M. D. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am. J. Med. 121, 885-893 (2008).
156. Ashrafian, H. et al. Metabolic surgery: an evolution through bariatric animal models. Obes. Rev. 11, 907-920 (2010).
157. Michell, A. R., Debnam, E. S. & Unwin, R. J. Regulation of renal function by the gastrointestinal tract: potential role of gut-derived peptides and hormones. Annu. Rev. Physiol. 70, 379-403 (2008).
158. Lennane, R. J., Carey, R. M., Goodwin, T. J. & Peart, W. S. A comparison of natriuresis after oral and intravenous sodium loading in sodium-depleted man: evidence for a gastrointestinal or portal monitor of sodium intake. Clin. Sci. Mol. Med. 49, 437-440 (1975).
159. Patriti, A., Facchiano, E., Sanna, A., Gulla, N. & Donini, A. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes. Surg. 14, 840-848 (2004).
160. Ashrafian, H. et al. Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes. Rev. 12, e257-e272 (2011).
161. Ashrafian, H., Darzi, A. & Athanasiou, T. Autobionics: a new paradigm in regenerative medicine and surgery. Regen. Med. 5, 279-288 (2010).
162. Ashrafian, H. et al. Metabolic surgery and obstructive sleep apnoea: the protective effects of bariatric procedures. Thorax 67, 442-449 (2012).
163. Kardassis, D. et al. Impact of body composition, fat distribution and sustained weight loss on cardiac function in obesity. Int. J. Cardiol. 159, 128-133 (2012).
164. MacMahon, S. W., Wilcken, D. E. & Macdonald, G. J. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N. Engl. J. Med. 314, 334-339 (1986).
165. McCloskey, C. A. et al. Bariatric surgery improves cardiac function in morbidly obese patients with severe cardiomyopathy. Surg. Obes. Relat. Dis. 3, 503-507 (2007).
166. Huffman, C., Wagman, G., Fudim, M., Zolty, R. & Vittorio, T. Reversible cardiomyopathies-a review. Transplant. Proc. 42, 3673-3678 (2010).
167. Pontiroli, A. E., Frige, F., Paganelli, M. & Folli, F. In morbid obesity, metabolic abnormalities and adhesion molecules correlate with visceral fat, not with subcutaneous fat: effect of weight loss through surgery. Obes. Surg. 19, 745-750 (2009).
168. Ashrafian, H., Athanasiou, T. & le Roux., C. W. Heart remodelling and obesity: the complexities and variation of cardiac geometry. Heart 97, 171-172 (2011).
169. Barraclough, M. A. & Bloom, S. R. Vipoma of the pancreas: observations on the diarhrhea and circulatory disturbances. Arch. Intern. Med. 139, 467-471 (1979).
170. Chatelain, P., Robberecht, P., de Neef, P., Claeys, M. & Christophe, J. Low responsiveness of cardiac adenylate cyclase activity to peptide hormones in spontaneously hypertensive rats. FEBS Lett. 107, 86-90 (1979).
171. le Roux., C. W. et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann. Surg. 243, 108-114 (2006).
172. Nikolaidis, L. A. et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109, 962-965 (2004).
173. Nikolaidis, L. A. et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110, 955-961 (2004).
174. Baessler, A. et al. Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease. Hum. Mol. Genet. 16, 887-899 (2007).
175. Nagaya, N. et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110, 3674-3679 (2004).
176. Tauber, M. et al. Hyperghrelinemia is a common feature of Prader-Willi syndrome and pituitary stalk interruption: a pathophysiological hypothesis. Horm. Res. 62, 49-54 (2004).
177. Löfgren, P. et al. Long-term prospective and controlled studies demonstrate adipose tissue hypercellularity and relative leptin deficiency in the postobese state. J. Clin. Endocrinol. Metab. 90, 6207-6213 (2005).
178. Linscheid, P. et al. Increase in high molecular weight adiponectin by bariatric surgery-induced weight loss. Diabetes Obes. Metab. 10, 1266-1270 (2008).
179. Meyer, T. E. et al. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J. Am. Coll. Cardiol. 47, 398-402 (2006).
180. Pories, W. J. et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann. Surg. 222, 339-350; discussion 350-352 (1995).
181. Hoerger, T. J., Segel, J. E., Gregg, E. W. & Saaddine, J. B. Is glycemic control improving in US adults? Diabetes Care 31, 81-86 (2008).
182. Knowler, W. C. et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374, 1677-1686 (2009).
183. Buchwald, H. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292, 1724-1737 (2004).
184. Fenske, W. K. et al. Can. a protocol for glycaemic control improve type 2 diabetes outcomes after gastric bypass? Obes. Surg. 22, 90-96 (2012).
185. Laferrere, B. et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93, 2479-2485 (2008).
186. Korner, J., Bessler, M., Inabnet, W., Taveras, C. & Holst, J. J. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg. Obes. Relat. Dis. 3, 597-601 (2007).
187. Schauer, P. R. et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann. Surg. 238, 467-484; discussion 84-85 (2003).
188. Wang, Y. & Liu, J. Combination of bypassing stomach and vagus dissection in high-fat diet-induced obese rats-a long-term investigation. Obes. Surg. 20, 375-379 (2010).
189. Tonosaki, K., Hori, Y. & Shimizu, Y. Relationships between insulin release and taste. Biomed. Res. 28, 79-83 (2007).
190. Jialal, I., Abby, S. L., Misir, S. & Nagendran, S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab. Syndr. Relat. Disord. 7, 255-258 (2009).
191. Mutch, D. M. et al. Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS ONE 4, e7905 (2009).
192. Kopp, H. P. et al. Impact of weight loss on inflammatory proteins and
193. Ashrafian, H. & le Roux., C. W. Metabolic surgery and gut hormones - a review of bariatric entero-humoral modulation. Physiol. Behav. 97, 620-631 (2009).
194. Mingrone, G. et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N. Engl. J. Med. 366, 1577-1585 (2012).
195. Schauer, P. R. et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N. Engl. J. Med. 366, 1567-1576 (2012).
196. Ballantyne, G. H., Gumbs, A. & Modlin, I. M. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes. Surg. 15, 692-699 (2005).
197. Gumbs, A. A., Modlin, I. M. & Ballantyne, G. H. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes. Surg. 15, 462-473 (2005).
198. Wickremesekera, K., Miller, G., Naotunne, T. D., Knowles, G. & Stubbs, R. S. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes. Surg. 15, 474-481 (2005).
199. Muscelli, E. et al. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am. J. Med. 118, 51-57 (2005).
200. Service, G. J. et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N. Engl. J. Med. 353, 249-254 (2005).
201. Z'Graggen, K. et al. Severe recurrent hypoglycemia after gastric bypass surgery. Obes. Surg. 18, 981-988 (2008).
202. Anstee, Q. M., McPherson, S. & Day, C. P. How big a problem is non-alcoholic fatty liver disease? BMJ 343, d3897 (2011).
203. Edmison, J. & McCullough, A. J. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin. Liver Dis. 11, 75-104 (2007).
204. Bugianesi, E. et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123, 134-140 (2002).
205. Day, C. P. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin. Med. 6, 19-25 (2006).
206. Dixon, J. B., Bhathal, P. S., Hughes, N. R. & O'Brien, P. E. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 39, 1647-1654 (2004).
207. Sjostrom, L. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004).
208. Benaiges, D. et al. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile. Obes. Surg. 22, 1268-1275 (2012).
209. Nguyen, N. T. et al. Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass. J. Am. Coll. Surg. 203, 24-29 (2006).
210. Holdstock, C. et al. CRP reduction following gastric bypass surgery is most pronounced in insulin-sensitive subjects. Int. J. Obes. (Lond.) 29, 1275-1280 (2005).
211. Vilarrasa, N. et al. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-alpha receptors, C-reactive protein and adiponectin in morbidly obese patients. Clin. Endocrinol. (Oxf.) 67, 679-686 (2007).
212. Morales, E., Valero, M. A., Leon, M., Hernandez, E. & Praga, M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am. J. Kidney Dis. 41, 319-327 (2003).
213. Chagnac, A. et al. The effects of weight loss on renal function in patients with severe obesity. J. Am. Soc. Nephrol. 14, 1480-1486 (2003).
214. Agnani, S., Vachharajani, V. T., Gupta, R., Atray, N. K. & Vachharajani, T. J. Does treating obesity stabilize chronic kidney disease? BMC Nephrol. 6, 7 (2005).
215. Solerte, S. B., Fioravanti, M., Schifino, N. & Ferrari, E. Effects of diet-therapy on urinary protein excretion albuminuria and renal haemodynamic function in obese diabetic patients with overt nephropathy. Int. J. Obes. 13, 203-211 (1989).
216. Praga, M. & Morales, E. Obesity, proteinuria and progression of renal failure. Curr. Opin. Nephrol. Hypertens. 15, 481-486 (2006).
217. Navarro-Diaz, M. et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J. Am. Soc. Nephrol. 17, S213-S217 (2006).
218. Agrawal, V. et al. The effect of weight loss after bariatric surgery on albuminuria. Clin. Nephrol. 70, 194-202 (2008).
219. Saliba, J. et al. Roux-en-Y gastric bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics. Surgery 147, 282-287 (2010).
220. Ruggenenti, P., Perna, A., Ganeva, M., Ene-Iordache, B. & Remuzzi, G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J. Am. Soc. Nephrol. 17, 3472-3481 (2006).
221. Navaneethan, S. D. et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Systematic Reviews, Issue 2. Art. No.: CD007784 http://dx.doi.org/10.1002/ 14651858.CD007784.
222. Alexander, J. W., Goodman, H. R., Hawver, L. R. & Cardi, M. A. Improvement and stabilization of chronic kidney disease after gastric bypass. Surg. Obes. Relat. Dis. 5, 237-241 (2009).
223. Gore, J. L. Obesity and renal transplantation: is bariatric surgery the answer? Transplantation 87, 1115 (2009).
224. Takata, M. C. et al. Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation. Surg. Obes. Relat. Dis. 4, 159-164; discussion 164-165. (2008).